ASCO GU 2024

Is "more" always better?

Cabo + IO: Interesting but not practice changing?!

BRCAAway - practice changing or hypothesis generating data?

Combination vs. monotherapy - a great new option for high-risk patients

Salvage radiation with anti-androgen superior to radiation alone

BRCAaway - PARP combination study

Further testing before olaparib combination

What about the clinical benefit?

Evaluating the recombination-repair mutations in patients with mCRPC

Gleason 3+3 - cancer or not?

Higher radiation is effective in high-risk PCA

Enzalutamide therapy as option for biochemical recurrence

Combination of cabozantinib & checkpoint inhibitor

Long-term dose escalation - Therapy in high-risk prostate cancers

Combination NHT + PARP makes sense

Still a difficult time for androgenic inhibitors in mCRPC

Relugolix combined with androgen signaling in real word experience

Dose de-escalation in different ways

Therapy Intensification Still Neglected in mHSPC

Olaparib + Arbiraterone better compared to either alone

Stockholm3 validated in multiethnic cohort

Localized PCa - news for radiotherapy and biochemical recurrence

Cognitive function in ART treatment

First positive study of IO therapy in mCRPC

Quality of life under intensive therapy

Insights and news for mCRPC

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

Kognitiv påverkan av abirateron och enzalutamid?

Kombination av cabozantinib och immunterapi

Post-RP salvage radyoterapi hormonoterapi ile konbine edilmeli

BRCAAway - PARP hämmare, abiraterone eller i kombination

SEPTA calismasi: Stockholm3 un multietnik hasta grubunda validasyonu

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO GU '24

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi)

Orta riskli PCa da RARP sirasinda LND dan vazgecilebilir mi?

Gleason 3+3 ska vi kalla de cancer eller inte?

Une période encore difficile pour les inhibiteurs androgéniques dans le cancer de la prostate métastatique résistant à la castration.

New standard of care, but still open questions!

ADC + ICI: new data for platinum-refractory bladder cancaer patients

The emerging field of biomarkers in bladder cancer

Advances in (neo)-adjuvant treatment in urothelial cancer

Another success for an ICI?

HER2 and bladder cancer

Should we start forgetting the Galsky Criteria in advanced urothelial carcinoma?

Adjuvant therapy in urothelial carcinoma : is the equation resolved?

Perioperative adjuvant therapy in urothelial cancer

Biomarker update

MIBC: adjuvant PD1 - all set?!

EV as standard in 3rd line mUC

ASCO GU24 - Highlights in Bladder cancer

Update on EV-302

Adjuvant Nivolumab Shows Promise in Boosting Long-Term Survivorship for High-Risk Muscle-Invasive Urothelial Carcinoma

Pembrolizumab adjuvant in bladder cancer

EV + Pembro new first-line standard in localized metastatic bladder cancer

Update M1 urothelial cancer

Highlights in bladder cancer at ASCO GU24

Encore un succès pour une ICI ?

Tratamiento adyuvante en cancer urotelial: ¿está resuelta la ecuación?

¿Deberíamos empezar a olvidarnos de los Criterios de Galsky en cancer urotelial avanzado?

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Terapia adyuvante perioperatoria en el cáncer de vejiga

Novedades sobre EV-302

Adjuvant therapy in kidney cancer: Is immunotherapy the answer?

No surprise with the QoL data

Subcutaneous vs. intravenous application: ready for everyday clinics?

Trial updates at ASCO GU24: Are the follow-up data confirmatory?

Long-Term Data on NIVO+IPI in aRCC

Durable effects of Ipi-Nivo

Overall survival benefit - Pembro after surgery

Tumorburden and outcome

Perioperative treatment in renal cell carcinoma - did we close the circle?

Better QoL with Belzutifan

Belzutifan: Updates on QoL

Highlights in kidney cancer at ASCO GU24

Long-term follow-up of first-line trials

Cabozantinib Plus Atezolizumab in Adrenocortical Carcinoma Falls Short of Expectations, Emphasizing Ongoing Need for Treatment Innovations

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark CheckMate-9ER Trial: Prolonged Efficacy and Safety Reinforce Standard of Care in Advanced Renal Cell Carcinoma

ASCO GU24 - Highlights in renal cell carcinoma

Long-term outcome

Subcutaneous Nivolumab Matches IV Formulation in Clear Cell Renal Cell Carcinoma, Paving the Way for Enhanced Therapy Delivery and Safety

Practice changing adjuvant therapy?!

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Tratamiento perioperatorio en cancer renal: ¿Hemos cerrado el círculo?